Summit Therapeutics (SMMT) Cash & Equivalents (2016 - 2025)
Historic Cash & Equivalents for Summit Therapeutics (SMMT) over the last 10 years, with Q3 2025 value amounting to $238.6 million.
- Summit Therapeutics' Cash & Equivalents rose 15438.98% to $238.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $238.6 million, marking a year-over-year increase of 15438.98%. This contributed to the annual value of $104.9 million for FY2024, which is 4681.41% up from last year.
- Per Summit Therapeutics' latest filing, its Cash & Equivalents stood at $238.6 million for Q3 2025, which was up 15438.98% from $297.9 million recorded in Q2 2025.
- Over the past 5 years, Summit Therapeutics' Cash & Equivalents peaked at $348.6 million during Q4 2022, and registered a low of $23.8 million during Q3 2023.
- In the last 5 years, Summit Therapeutics' Cash & Equivalents had a median value of $98.0 million in 2021 and averaged $124.5 million.
- Its Cash & Equivalents has fluctuated over the past 5 years, first crashed by 8049.37% in 2023, then skyrocketed by 94759.09% in 2025.
- Over the past 5 years, Summit Therapeutics' Cash & Equivalents (Quarter) stood at $71.8 million in 2021, then soared by 385.59% to $348.6 million in 2022, then tumbled by 79.51% to $71.4 million in 2023, then surged by 46.81% to $104.9 million in 2024, then soared by 127.49% to $238.6 million in 2025.
- Its Cash & Equivalents stands at $238.6 million for Q3 2025, versus $297.9 million for Q2 2025 and $211.5 million for Q1 2025.